The Institute Research fields Technical platforms Why come to INM? News & press

U 844

U 1051

Team 1
Genetics and therapy of retinal blindness and optic nerve

Team 2
Pathophysiology and therapy of the inner ear

Team 3
Neural differentiation and connectivity in the somatosensory system

Team 4
Plasticity, stem cells and glial tumors

Team 5
Amyotrophic lateral sclerosis: neuroinflammation and therapy

Avenir Team 1
Somato-sensory specification

Avenir Team 2
Molecular mechanisms of myelination/demyelination and gene therapy approaches in peripheral nerves

Avenir Team 3
The Ubiquitin Proteasome System in neurodegeneration and cytoskeleton architecture


 

 

| Home | Contact | Legal |    

Research fields

AVENIR team 3

The Ubiquitin Proteasome System in
neurodegeneration and cytoskeleton architecture


Group leader
BOMONT Pascale

pascale.bomont@inserm.fr
Tel +33 (0)4 99 63 60 73

Members
Scientists
BOMONT Pascale

Postdoctoral fellows
Prasanna Iyengar

PhD student
André Lopes

Master students
PEYRESSATRE Marion

Engineers
BOIZOT Alexia

 

 

 


The Ubiquitin Proteasome System (UPS) is impaired in many neurodegenerative disorders and its role in neurodegeneration is the focus of intense scrutiny. However, solving its implication in neuronal death represents a considerable challenge and systems in which neurodegeneration is directly caused by mutations in component(s) of the UPS are very valuable models for this aim.

The identification of gigaxonin, the substrate adaptor of a Cul3-E3 ubiquitin ligase, as the defective protein in the fatal neurodegenerative disorder Giant Axonal Neuropathy (GAN), prompted us to choose this model as a direct way to study the role of the UPS in neurodegeneration. The broad degeneration of the nervous system together with the generalized disorganization of Intermediate Filaments in patients, point to a key role for gigaxonin in sustaining both neuronal survival and cytoskeleton architecture.

Our group is dedicated to deciphering the pathophysiology of GAN but also to developing a specific diagnostic test and the first therapeutic approaches for this fatal disease. We are studying the pathways of cell death and cytoskeleton dynamics in new neuronal models that are also used as readout tests to evaluate the efficacy of therapeutic vehicules generated by our collaborators. We are using multidisciplinary approaches encompassing human genetics, cell biology, biochemistry and animal models.

 


Main publications


Ganay T, Boizot A, Burrer R, Chauvin JP, and Bomont P. Sensory-motor deficits and Neurofilament disorganization in Gigaxonin-null mice. Mol Neurodegener.12;6:25. (2011)


Cleveland DW, Yamanaka K, Bomont P. (2009) Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway. Hum Mol Genet. 18(8):1384-94. (2009)


Bomont P
, Koenig M. (2003). Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.
Hum Mol Genet. 12(8):813-22. (2003)


Bomont P
, Cavalier L, Blondeau F et al.. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet. 26(3):370-4. (2000)

Full publication record

http://www.ncbi.nlm.nih.gov/pubmed/?term=bomont+p

         
         

Top

The Institute | Research fields | Technical platforms |
Why come to INM? | News / Press | Contact |
Home | Site map |  Legal & credits
Publication Head: Christian Hamel
Copyright © INM 2006